GEBURTSHILFE UND FRAUENHEILKUNDE is a prestigious journal dedicated to the fields of Maternity, Midwifery, Obstetrics, and Gynecology, published by GEORG THIEME VERLAG KG, a reputable publisher known for its commitment to advancing medical knowledge. Established in 1947, the journal has consistently provided a platform for high-quality research and clinical studies that address current challenges and innovations in women's health. With an impact factor positioned in Q2 for Maternity and Midwifery and Q3 in Obstetrics and Gynecology, it ranks among the top journals within its field, further solidified by its Scopus rankings highlighting its influential presence. Although the journal is not open access, it remains an essential resource for academics and practitioners keen to stay informed on the latest evidence-based practices and cutting-edge research, ensuring that all stakeholders in women's healthcare can access critical insights to enhance patient outcomes.

Current Opinion in Supportive and Palliative Care, an esteemed journal published by Lippincott Williams & Wilkins, provides a vital platform for the dissemination of contemporary research and expert perspectives in the fields of supportive and palliative care. As part of the medical community's growing focus on critical care and oncology, this journal has earned its place in the Q2 category across multiple rankings, reflecting its influence and significance in advancing knowledge and practices. With its ISSN 1751-4258 and E-ISSN 1751-4266, it covers literature from 2007 to 2024, making it a reliable resource for the latest developments. While it does not offer open access, the journal ensures careful curating of high-quality articles, fostering a deeper understanding of complex care needs. Researchers, clinicians, and students alike will benefit from the journal's insights, exploring innovative strategies and multidisciplinary approaches to improve patient outcomes in critical situations. The commitment to such a crucial area of healthcare underscores the importance of this publication in shaping future practices and policies.

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

Cancer Epidemiology, published by ELSEVIER SCI LTD, serves as a premier platform for disseminating innovative research in the areas of cancer epidemiology and oncology. Operating from the Netherlands, this journal provides a critical insight into the factors influencing cancer incidence, including genetic, environmental, and lifestyle variables. With an impact factor reflecting its significance in the field, it holds a respectable Q2 ranking in Cancer Research, Epidemiology, and Oncology. The journal spans a wide range of topics and publishes studies that aim to bridge gaps in existing literature through rigorous research methodologies. Researchers and professionals interested in acquiring the latest insights and contributing to the evolving discourse on cancer epidemiology will find this journal an invaluable resource. Access to articles may be available through open access options, ensuring the widest dissemination of knowledge.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

CA: A Cancer Journal for Clinicians is a prestigious academic journal published by Wiley, serving as a leading source of evidence-based information for those in the fields of oncology and hematology. With an impressive impact factor and ranked in the top quartile (Q1) for both specialties, this journal aims to bridge the gap between the latest research findings and clinical practice. Established in 1950, it boasts a long-standing history of delivering essential insights, guidelines, and innovative strategies to healthcare professionals worldwide, making significant contributions to the understanding and treatment of cancer. Although it does not offer open access, its published content is crucial for researchers, clinicians, and students dedicated to advancing cancer care. The journal's commitment to excellence is reflected in its elite rankings, holding the #1 position in both the Medicine – Oncology and Medicine – Hematology categories according to Scopus, positioning it in the 99th percentile of scholarly impact.

JMIR Cancer is a premier open access journal published by JMIR Publications, Inc., dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has become an invaluable resource for researchers, clinicians, and students alike, providing a platform for the dissemination of cutting-edge research and clinical insights. Operating out of Canada, JMIR Cancer holds noteworthy rankings, including a Q3 position in Cancer Research and Q2 in Oncology as of 2023, highlighting its significant contribution to the scientific community. With the journal's open access model, articles are made freely available, ensuring that vital research reaches a wide audience and fosters collaboration across disciplines. By focusing on innovative research, translational studies, and clinical practices related to cancer, JMIR Cancer aims to be at the forefront of knowledge translation and tumor biology, bridging the gap between laboratory findings and patient care.

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.